V. Bozon

发表

Phase I/II trial of tremelimumab in patients with metastatic melanoma.

B. Redman, J. Sosman, J. Kirkwood, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

364 First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAF/NRAS-mutant melanoma

J. Larkin, R. Plummer, M. Kneissl, 2014 .

Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma.

A. Ribas, L. Gordon, J. Gómez-Navarro, 2007, American journal of ophthalmology.

Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma.

D. Schadendorf, K. Flaherty, P. Ascierto, 2016 .

Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).

C. Berking, P. Ascierto, J. Sosman, 2017 .

Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma

A. Ribas, J. Reuben, L. Camacho, 2005 .

Therapy with human monoclonal anti-CTLA-4 antibody, CP-675,206, reduces regulatory T cells and IL-10 production in patients with advanced malignant melanoma (MM)

J. Reuben, L. Camacho, Bang‐Ning Lee, 2005 .

First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma.

J. Sosman, A. Ribas, P. LoRusso, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

D. Schadendorf, K. Flaherty, P. Ascierto, 2017, The Lancet. Oncology.

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors

R. Neuwirth, J. Sosman, A. Ribas, 2016, Investigational New Drugs.

BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.

Junfeng Xia, Peilin Jia, William Pao, 2012, Cancer discovery.

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

B. Comin-Anduix, A. Ribas, L. Camacho, 2008, Journal of Translational Medicine.

Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanoma

J. Reuben, L. Camacho, Bang‐Ning Lee, 2006, Cancer.

Objective Radiographic Response to MEK Inhibitor Therapy in a Patient with a Metastatic Melanoma with a BRAF

Zhongming Zhao, J. Netterville, P. Jia, 2012 .

Phase I clinical trials of ticilimumab: Tumor responses are sufficient but not necessary for prolonged survival.

A. Ribas, L. Camacho, J. Gómez-Navarro, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose and schedule selection for the anti-CTLA4 monoclonal antibody ticilimumab in patients (pts) with metastatic melanoma.

A. Ribas, L. Camacho, J. Gómez-Navarro, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1b/2 study of binimetinib (BINI) in combination with nivolumab (NIVO) or NIVO plus ipilimumab (IPI) in patients (pts) with previously treated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) with RAS mutation.

S. Kopetz, J. Bendell, M. Middleton, 2018 .

Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.

R. Neuwirth, J. Sosman, A. Ribas, 2013 .

Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma

J. Larkin, R. Plummer, M. Kneissl, 2023, Cancer Chemotherapy and Pharmacology.

A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of FN-1501 monotherapy in patients with advanced solid tumors.

A. Hui, U. Vaishampayan, S. Williamson, 2019, Journal of Clinical Oncology.

A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors.

T. Yap, G. Falchook, S. Parasuraman, 2021 .

866 RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in preclinical models and patient tumors

T. Yap, R. Abo, G. Falchook, 2021, Journal for ImmunoTherapy of Cancer.

MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors: Phase I study.

R. Neuwirth, M. Kneissl, D. Rasco, 2013 .